PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

Published:2015-12-07 Issue:23 Volume:35 Page:2961-2970
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Cheng H,Liu P,Ohlson C,Xu E,Symonds L,Isabella A,Muller W J,Lin N U,Krop I E,Roberts T M,Winer E P,Arteaga C L,Zhao J J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2015377.pdf

Reference36 articles.

1. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L . Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011; 9: 16–32.

2. Baselga J, Swain SM . Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463–475.

3. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269–280.

4. Lerma E, Catasus L, Gallardo A, Peiro G, Alonso C, Aranda I et al. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 2008; 453: 133–139.

5. Hynes NE, Dey JH . PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 2009; 15: 353–355.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

2. Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities;Acta Pharmacologica Sinica;2024-02-15

3. Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis;Journal of Cancer Research and Clinical Oncology;2024-01-27

4. The p110α/ΔNp63α complex mutations in triple-negative breast cancer: Potential targets for transcriptional-based therapies;Tumor Biology;2023-11-13

5. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges;Cancer Treatment Reviews;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3